Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer

doi:10.4251/wjgo.v15.i1.143

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2484)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

123

WORD

HTML

1335

Figures (1-3)

227

Tables (1-6)

208

Sum=1942

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

162

Download

380

Sum=542

Jan 15, 2023 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jan 15, 2023; 15(1): 143-154
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.143

Full Size Figure Download Figure

Figure 1 Trend chart of tumor markers before and after treatment in two groups. A: Carbohydrate antigen 199; B: Carcinoembryonic antigen; C: Neuron-specific enolase; D: Epidermal growth factor receptor. CA199: Carbohydrate antigen 199; CEA: Carcinoembryonic antigen; NSE: Neuron-specific enolase; EGFR: Epidermal growth factor receptor.

Citation: Wang JP, Du JL, Li YY. Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer. World J Gastrointest Oncol 2023; 15(1): 143-154
URL: https://www.wjgnet.com/1948-5204/full/v15/i1/143.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i1.143